Treatment-Resistant Depression Entering Remission Following a Seizure during the Course of Repetitive Transcranial Magnetic Stimulation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Major depressive disorder is often resistant to antidepressant treatment. Repetitive transcranial magnetic stimulation (rTMS) has been used in treatment-resistant depression (TRD). Known adverse events of rTMS include transient headache, local pain, syncope, seizure induction, and hypomania induction. This report outlines a patient with TRD who unexpectedly improved following a seizure during the course of rTMS, which has never been reported.
Abstract
Major depressive disorder is often resistant to antidepressant treatment. Repetitive transcranial magnetic stimulation (rTMS) has been used in treatment-resistant depression (TRD). Known adverse events of rTMS include transient headache, local pain, syncope, seizure induction, and hypomania induction. This report outlines a patient with TRD who unexpectedly improved following a seizure during the course of rTMS, which has never been reported.
참고문헌 (31)
- Kessler RC, "The epidemiology of major depressive disorder : results from the National Comorbidity Survey Replication(NCS-R)", JAMA, 289, pp.3095~3105 (2003)
- Cassano P, "Depression and public health : an overview", J Psychosom Res, 53, pp.849~857 (2002)
- Riolo SA, "Prevalence of depression by race", ethnicity : findings from the national health and nutrition examination survey III, 2005, pp.95, 998~1000
- Frank E, "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Berlim MT, "Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods", Can J Psychiatry, 52, pp.46~54 (2007)
- Rush AJ, "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression", N Engl J Med, 354, pp.1231~1242 (2006)
- Fava M, "Diagnosis and definition of treatment-resistant depression", Biol Psychiatry, 53, pp.649~659 (2003)
- Souery D, "Treatment-resistant depression", J Clin Psychiatry, 67(Suppl 6), pp.16~22 (2006)
- Fava M, "New approaches to the treatment of refractory depression", J Clin Psychiatry, 61(Suppl 1), pp.26~32 (2000)
- Lefaucheur JP, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation(rTMS)", Clin Neurophysiol, 125, pp.2150~2206 (2014)
- George MS, "Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression", Am J Psychiatry, 168, pp.356~364 (2011)
- Ridding MC, "Is there a future for therapeutic use of transcranial magnetic stimulation?", Nat Rev Neurosci, 8, pp.559~567 (2007)
- Williams JA, "Updates on the use of non-invasive brain stimulation in physical and rehabilitation medicine", J Rehabil Med, 41, pp.305~311 (2009)
- Siebner HR, "Transcranial magnetic stimulation : new insights into representational cortical plasticity", Exp Brain Res, 148, pp.1~16 (2003)
- Loo CK, "A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression", Int J Neuropsychopharmacol, 11, pp.131~147 (2008)
- Janicak PG, "Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduc tion treatment", J Clin Psychiatry, 69, pp.222~232 (2008)
- Rossi S, "Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research", Clin Neurophysiol, 120, pp.2008~2039 (2009)
- Rasmussen K, "The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging", J ECT, 18, pp.58~59 (2002)
- Husain MM, "Speed of response and remission in major depressive disorder with acute electroconvulsive therapy(ECT) : a consortium for research in ECT(CORE)Report", J Clin Psychiatry, 65, pp.485~491 (2004)
- Altar CA, "Effects of electroconvulsive seizure and antidepressants on BDNF protein in rat brain", Biol Psychiatry, 54, pp.703~709 (2003)
- Altar CA, "electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways", J Neurosci, 24, pp.2667~2677 (2004)
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- "Transcranial magnetic stimulation for severe depression"[URL]
- Schlaepfer TE, "WFSBP guidelines on brain stimulation treatments in psychiatry", World J Biol Psychiatry, 11, pp.2~18 (2010)
- Belmaker B, "Managing the risks of repetitive transcranial stimulation", CNS Spectr, 8, pp.489~ (2003)
- Kayser S, "Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects", Psychol Med, 45, pp.1073~1092 (2015)
- Sadock BJ, "Kaplan & Sadock’s Synopsis of Psychiatry", pp.1065~1081 (2014), Wolters Kluwer
- Rasmussen KG, "An open-label, pilot study of daily right unilateral ultrabrief pulse electroconvulsive therapy", J ECT, 32, pp.33~37 (2016)
- Wahlestedt C, "Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y(NPY)-like immunoreactivity in the rat", Brain Res, 507, pp.65~68 (1990)
